Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity

Affiliations

¹ CHU Lille, Service de Dermatologie, Lille, France.
² Service de Dermatologie, Hôpital Larrey, CHU de Toulouse, Toulouse, France.
³ Allergologie et Immunologie Clinique, Hôpital Lyon-Sud, CIRI Inserm U1111, Lyon, France.
⁴ Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France.
⁵ Dermatologie, Hôpital Saint-Louis AP-HP, Paris, France.
⁶ Dermatologie et Allergologie, Hôpital Tenon AP-HP, Paris, France.
⁷ Dermatologie, CHU Rouen, Rouen, France.
⁸ Dermatologie, CHU Besançon, Besançon, France.
⁹ Dermatologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
¹⁰ Dermatologie, C.H. U de Montpellier, Montpellier, France.
¹¹ Dermatologie, C.H. U de Toulouse, Toulouse, France.
¹² Department of Dermatology, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, Environnement et Travail) - UMR_S 1085, Rennes, France.
¹³ Dermatologie, Hôpital le Bocage, Dijon, France.
¹⁴ Dermatologie, CHU Nantes, Nantes, France.
¹⁵ Nantes Université, Department of Dermatology, CHU Nantes, INRAE, UMR 1280, PhAN, Nantes, France.
¹⁶ Dermatologie, Hôpital Henri-Mondor AP- HP, Créteil, France.
¹⁷ Dermatologie, Hopital Archet 2, Nice, France.
¹⁸ Dermatologie, CH de Douai, Douai, France.
¹⁹ Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France.
²⁰ Facial Dermatosis Clinic, AP-HP, University-Hospital La Pitié-Salpêtrière, Paris, France.

Joséphine Dupuis et al. J Eur Acad Dermatol Venereol. 2025 Feb.

. 2025 Feb;39(2):e174-e178.

doi: 10.1111/jdv.20264. Epub 2024 Jul 31.

¹ CHU Lille, Service de Dermatologie, Lille, France.
² Service de Dermatologie, Hôpital Larrey, CHU de Toulouse, Toulouse, France.
³ Allergologie et Immunologie Clinique, Hôpital Lyon-Sud, CIRI Inserm U1111, Lyon, France.
⁴ Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France.
⁵ Dermatologie, Hôpital Saint-Louis AP-HP, Paris, France.
⁶ Dermatologie et Allergologie, Hôpital Tenon AP-HP, Paris, France.
⁷ Dermatologie, CHU Rouen, Rouen, France.
⁸ Dermatologie, CHU Besançon, Besançon, France.
⁹ Dermatologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
¹⁰ Dermatologie, C.H. U de Montpellier, Montpellier, France.
¹¹ Dermatologie, C.H. U de Toulouse, Toulouse, France.
¹² Department of Dermatology, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, Environnement et Travail) - UMR_S 1085, Rennes, France.
¹³ Dermatologie, Hôpital le Bocage, Dijon, France.
¹⁴ Dermatologie, CHU Nantes, Nantes, France.
¹⁵ Nantes Université, Department of Dermatology, CHU Nantes, INRAE, UMR 1280, PhAN, Nantes, France.
¹⁶ Dermatologie, Hôpital Henri-Mondor AP- HP, Créteil, France.
¹⁷ Dermatologie, Hopital Archet 2, Nice, France.
¹⁸ Dermatologie, CH de Douai, Douai, France.
¹⁹ Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France.
²⁰ Facial Dermatosis Clinic, AP-HP, University-Hospital La Pitié-Salpêtrière, Paris, France.

No abstract available

References

1. Clot PF, Kamal M, Sun J, Xu C, Kong F, Gu Y, et al. Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: results of two randomized, double‐blind, placebo‐controlled studies. Int Immunopharmacol. 2021;99:107985.
1. Kovalenko P, DiCioccio AT, Davis JD, Li M, Ardeleanu M, Graham N, et al. Exploratory population PK analysis of Dupilumab, a fully human monoclonal antibody against IL‐4Rα, in atopic dermatitis patients and normal volunteers. CPT Pharmacometrics Syst Pharmacol. 2016;5(11):617–624.
1. Davis DMR, Drucker EM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. American Academy of Dermatology guidelines: awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022;86(6):1335–1336.e18.
1. Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real‐life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–151.
1. Bosma AL, de Wijs LEM, Hof MH, van Nieuwenhuizen BR, Gerbens LAA, Middelkamp‐Hup MA, et al. Long‐term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol. 2020;83(5):1375–1384.